ARQL News and Press, ArQule Inc. From 12/16/19

Merck ( MRK ) had announced that it would purchase ArQule ( ARQL ) for a total of $2.7 billion or $20 per share in cash. The main goal for this acquisition was that Merck could add a precision medicine oncology biotech to its portfolio. This acquisition should help the oncology portfol...

Merck (NYSE: MRK) and Eli Lilly (NYSE: LLY) are two of the largest pharmaceutical companies in the world, and both provide decent prospects for investors. Comparing the two over the past 12 months does yield a clear winner from Wall Street's perspective, though. Merck -- whose shares a...

NEW YORK, NY / ACCESSWIRE / December 11, 2019 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City, is investigating: Instructure, Inc (NYSE: INST ) related to...

I’ve written before that I consider Aptose Biosciences ( APTO ) to be a “speculation worth considering” on the strength of its two-drug pipeline for hematology, and between Merck ’s ( MRK ) $2.7 billion bid for ArQule ( ARQL ) and encouraging early-stage data...

Merck ( MRK ) continues to employ M&A to bolster its leading position in oncology, as it has acquired ArQule ( ARQL ) in what seems to be quite an aggressive move to add to its pipeline. Despite the aggressiveness, ArQule is just a bolt-on acquisition for a firm the size of Merck which...

December 10, 2019 Palm Beach, FL –December 10, 2019 – Much R&D from companies and investors has been pouring into the targeted drug therapies markets, enabling pharma companies and other industry researchers to find better and more effective ways to combat cancer in ...

Major benchmarks drifted lower Monday as uncertainty over a trade deal continued to weigh on the market. The  Dow Jones Industrial Average (DJINDICES: ^DJI)  and the  S&P 500 (SNPINDEX: ^GSPC)  closed near session lows. Data source: Yahoo! Finance. As for individual...

The Internet Pounces on their Marketing and Peloton Stock Suffers Last week the Twitterverse stormed and condemned Peloton ( PTON ). It has been the target of satirical YouTube videos; Aviation Gin even created a YouTube ad spoofing Peloton and drafting off of PTON’s misery. Has PTO...

Gainers: Synthorx (NASDAQ: THOR )  +170% . More news on: Synthorx, Inc., ArQule, Inc., Forty Seven, Inc., Stocks on the move, Read more ...

NEW YORK, Dec. 09, 2019 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of ArQule, Inc. (NASDAQ: ARQL) to Merck for $20.00 per share is fair to ArQule shareholders. On behalf of ArQule shareholders, Halper Sadeh LLP may seek increas...